Skip Navigation

European Journal of Heart Failure 2005 7(7):1145-1148; doi:10.1016/j.ejheart.2004.12.009
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Del Ry, S.
Right arrow Articles by Giannessi, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Del Ry, S.
Right arrow Articles by Giannessi, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society of Cardiology

C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity

Silvia Del Ry, Claudio Passino, Maristella Maltinti, Michele Emdin and Daniela Giannessi*

Institute of Clinical Physiology, National Research Council Pisa, Italy

* Corresponding author. CNR Institute of Clinical Physiology, Via Giuseppe Moruzzi 1, Pisa 56124, Italy. Tel.: +39 50 3152664; fax: +39 50 3152166. E-mail address: danielag{at}ifc.cnr.it


   Abstract

Backgound: C-type natriuretic peptide (CNP), secreted by the endothelium and the heart, is structurally related to atrial and brain natriuretic peptides, but its clinical significance in chronic heart failure (CHF) is controversial.

Aim: To investigate the role of CNP in CHF, plasma CNP levels were determined in a prospective series of 133 patients with CHF (age 64±1 years, left ventricular ejection fraction (EF), 31.5±0.7%, mean±S.E.M.) and in 21 age-matched healthy subjects.

Methods and results: CNP was measured by a radioimmunoassay (sensitivity: 0.41±0.009 pg/tube) after a preliminary solid-phase extraction. Plasma level of CNP in healthy subjects was 2.7±0.2 pg/ml and significantly increased in CHF, as a function of clinical severity: 4.9±0.7 pg/ml in NYHA class I; 7.0±0.4 pg/ml in class II (p<0.001 vs. controls); 9.6±0.7 pg/ml in class III (p<0.001 vs. controls and class I and II), and 11.8±2.0 pg/ml in class IV (p<0.001 vs. controls, class I and II; Fisher's test after ANOVA). A significant relation was also found between CNP plasma levels and EF (R=0.40, p<0.001).

Conclusion: Plasma CNP elevation is related to clinical and functional disease severity. These findings suggest a pathophysiological role for this peptide that, for its vasorelaxing activity, could influence the endothelial vasomotor response in CHF.

Key Words: C-type natriuretic peptide (CNP) • Natriuretic peptides • Chronic heart failure (CHF)

Received September 16, 2004; Revised November 9, 2004; Accepted December 20, 2004


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
E. A. Heeb, R. S. Baker, C. Lam, M. Basu, W. Lubbers, J. Y. Duffy, and P. Eghtesady
Role of Natriuretic Peptides in cGMP Production in Fetal Cardiac Bypass.
Ann. Thorac. Surg., March 1, 2009; 87(3): 841 - 847.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. M. Dickey, D. R. Flora, P. M. Bryan, X. Xu, Y. Chen, and L. R. Potter
Differential Regulation of Membrane Guanylyl Cyclases in Congestive Heart Failure: Natriuretic Peptide Receptor (NPR)-B, Not NPR-A, Is the Predominant Natriuretic Peptide Receptor in the Failing Heart
Endocrinology, July 1, 2007; 148(7): 3518 - 3522.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.